ArticleAmerican journal of translational research2026
A retrospective cohort study on the improvement of urodynamic parameters and NIH-CPSI scores with Relin granules in BPH patients with high prostatitis-like symptom scores.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of Relin Granules combined with conventional therapy in improving urodynamic parameters, symptom scores, and inflammatory biomarkers in patients with benign prostatic hyperplasia (BPH) who have high prostatitis-like symptoms.
methodsThis retrospective cohort study enrolled 132 BPH patients with a National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score ≥15 who were treated between January 2023 and January 2025. Among them, 44 patients received conventional therapy plus Relin Granules (4 g tid, 12 weeks), and 88 received conventional therapy alone. Conventional treatment included the α-blocker tamsulosin and, in some patients, the 5α-reductase inhibitor finasteride. The primary outcomes were changes in NIH-CPSI, International Prostate Symptom Score (IPSS), and urodynamic parameters.
resultsAfter 12 weeks, the combination group showed significantly greater improvements in NIH-CPSI total score (adjusted difference -4.3, P<0.001), pain domain (-1.9, P<0.001) and quality of life domain (-1.4, P<0.001), while the urinary symptom domain did not differ significantly (P=0.056). Compared with the conventional group, the combination group had a greater reduction in IPSS total score (adjusted difference -2.1, P=0.004). No significant differences were observed in maximum flow rate (Qmax, adjusted difference 0.8 mL/s, P=0.342) or postvoid residual volume (PVR, 3.2 mL, P=0.415). The combination group showed significantly greater reductions in serum tumor necrosis factor-alpha (TNF-α) (adjusted difference -3.28 pg/mL, P<0.001) and urinary prostatic exosomal protein (PSEP) (-0.15 ng/mg, P=0.007), and a greater increase in interleukin-10 (IL-10) (1.89 pg/mL, P=0.012). Adverse event rates were similar (χ
conclusionIn BPH patients with high prostatitis-like symptoms, adding Relin Granules to conventional therapy was associated with alleviation of pain, improvement in quality of life and lower urinary tract symptoms (LUTS), potentially through anti-inflammatory mechanisms, with good safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.